In the light of the rapidly developing COVID-19 pandemic, we would like to provide the following information about the steps Abacus dx has taken in response to the virus outbreak:
Abacus ALS & Diagnostic Solutions are now Abacus dx
Brisbane, November 21, 2017, Abacus ALS Pty Ltd (Abacus ALS) and Diagnostic Solutions Pty Ltd (Diagnostic Solutions) today announced
Frequently Asked Questions:
Who do I contact if I have an ordering enquiry?
Please continue to contact Abacus ALS and Diagnostic Solutions as you have done previously. There are no changes to the contact phone numbers and email addresses you have been using.
In recent times the shareholders of Abacus ALS have been exploring options to transition away from the current shareholding of the business. We are pleased to announce that Diploma PLC has acquired Abacus ALS, and the company will be included in the Diploma Healthcare Group.
Six months after commencing our “Walking for Wellness” challenge, Abacus ALS staff have recently reached our milestone of walking over 3,500 kilometres to raise money for the Paraplegic Benefit Fund (PBF). We started the challenge back in July 2016 with the aim to help our staff increase their wellness, through being more active, whilst also raising money for this worthy cause.
Abacus ALS, the Brisbane based distributor of pathology and research laboratory instruments and consumables has announced that Shayne Christensen has been appointed Chief Executive Officer (CEO), effective January 1st 2013.
Abacus ALS staff recently took to the streets of Brisbane to participate in the MS Moonlight Walk and help in the fight against Multiple Sclerosis.
Abacus ALS has recently embarked on our Walking for Wellness campaign which is designed to encourage our staff to be more active and to raise money for the Paraplegic Benefit Fund.
Abacus ALS has been improving the healthcare outcomes for millions of Australians and New Zealanders for over 50 years.